{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964933",
  "id": "02964933",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250702",
  "time": "0942",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250702/pdf/06lcl2f18z4v40.pdf",
  "summary": "- **Additional Partial Response in ACCENT Trial**: Confirmed partial response (PR) observed, bringing total confirmed PRs to **16 out of 55 patients** (29% objective response rate).  \n- **Trial Status**: 20 patients still enrolled; further updates expected as data accrues.  \n- **Trial Focus**: Evaluating narmafotinib (FAK inhibitor) combined with gemcitabine/Abraxane\u00ae in advanced pancreatic cancer.  \n\n*(No material capital markets or trading-specific information identified; primarily clinical update.)*",
  "usage": {
    "prompt_tokens": 1197,
    "completion_tokens": 112,
    "total_tokens": 1309,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-01T23:56:28.071692"
}